Itau Unibanco Holding S.A.’s Adaptimmune Therapeutics ADAP Stock Holding History

Itau Unibanco Holding S.A.’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-7,434	Closed	-$13K	–	535
2022 Q2	$13K	Sell	7,434 -5,653	-43%	-$9.71K	﹤0.01%	409
2022 Q1	$27K	Hold	13,087	–	–	﹤0.01%	356
2021 Q4	$51K	Sell	13,087 -246	-2%	-$1.12K	﹤0.01%	280
2021 Q3	$69K	Buy	13,333 +4,441	+50%	+$19.9K	﹤0.01%	230
2021 Q2	$38K	Buy	+8,892	New	+$43.2K	﹤0.01%	230

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Itau Unibanco Holding S.A.'s ADAP Position: Q3 2022 in Review

Itau Unibanco Holding S.A. sold out of Adaptimmune Therapeutics (ADAP) in Q3 2022, closing a stake of 7,434 shares — an estimated $13K sold.

Itau Unibanco Holding S.A. first reported a position in ADAP in Q2 2021 and held it in 5 quarters. The position peaked at $69K in Q3 2021. 68 funds tracked by Wall St. Rank hold ADAP as of Q3 2022.

Itau Unibanco Holding S.A. reported no remaining Adaptimmune Therapeutics position as of Q3 2022 after selling out during the quarter.
Itau Unibanco Holding S.A. sold 7,434 Adaptimmune Therapeutics shares in Q3 2022, an estimated $13K.
Itau Unibanco Holding S.A. first reported a position in Adaptimmune Therapeutics in Q2 2021 and held it in 5 quarters.
Itau Unibanco Holding S.A.'s Adaptimmune Therapeutics position peaked at $69K in Q3 2021.
68 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2022.

Based on Itau Unibanco Holding S.A.'s 13F filing for Q3 2022, filed 14 Nov 2022.